After a trail in Britain showed the dexamethasone drug reduced the death rates in hospitalized patients, Japan’s health ministry has approved dexamethasone, a cheap and widely used steroid, as a second treatment of COVID-19.
The ministry included dexamethasone as an option for corona virus treatment along with Gilead Sciences Inc’s antiviral drug remdesivir in a recent revision to its handbook in Japan. The revision was widely reported by Japanese media on Wednesday and was viewed by Reuters.
Read Also – Majority of Japanese people reject govt. domestic tourism campaign
Recent reports shows that the shares of Nichi-Iko Pharmaceutical Co, among those that produce the drug, gained as much as 6.5% in early trade.
As scientists said its a major breakthrough in the coronavirus pandemic, Also as the results announced last month, a trial by researchers in the United Kingdom showed dexamethasone as the first drug to save lives of COVID-19 patients.
Last Friday, The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.